Joint AsCAP/EHTG Therapeutic Prevention Session

Date: Saturday 19 October 2019
Time: 15:30 – 18:30

Time Session
15:30 – 15:40 Introduction and setting the scene – Jack Cuzick (UK)
15:40 – 16:00 Cancer prevention and aspirin – the second decade – Peter Rothwell (UK)
16:00 – 16:10 CAPP2 the second decade – Sir John Burn (UK)
16:10 – 16:20 Benefits, harms and cost-effectiveness of aspirin chemoprevention in individuals with Lynch syndrome – Yoon-Jung Kang (Australia)
16:20 – 16:40 Aspirin for Precision Prevention of colorectal Cancer – Andy Chan (USA)
16:40 – 17:00 Group discussion
17:00 – 17:20 Panel testing for inherited cancer genes: which genes when?
17:20 – 17:40 Cancer prevention in Lynch syndrome: news from vaccination studies – Magnus von Knebel-Doeberitz (Germany)
17:40 – 18:00 How to asses cost/efficacy of alternative models for preventing / curing CRC – Yoon-Jung Kang (Australia)
18:00 – 18:20 Polygenic Risk scores – Jack Cuzick (UK)
18:20 – 18:30 Adjourn and Next Meeting Announcement
Top